Celldex Therapeutics (DB:TCE2) - Hisse Senedi Fiyatı, Haberler ve Analizler

TCE2 Stoklara Genel Bakış

Bir biyofarmasötik şirketi olan Celldex Therapeutics, Inc. çeşitli hastalıkların tedavisi için terapötik monoklonal ve bispesifik antikorlar geliştirmektedir. Daha fazla detay

TCE2 temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 74.83% oranında artması öngörülüyor

Risk Analizi

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Hissedarlar geçen yıl sulandırıldı

Son 3 ayda dalgalı hisse senedi fiyatı

Celldex Therapeutics, Inc. Rakipler

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€827.2m

Heidelberg Pharma

XTRA:HPHA

€103.9m

2invest

XTRA:2INV

€63.8m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Celldex Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$24.80
52 Haftanın En Yüksek Seviyesi	US$47.80
52 Haftanın En Düşük Seviyesi	US$21.80
Beta	1.59
11 Aylık Değişim	-6.77%
3 Aylık Değişim	-21.52%
1 Yıllık Değişim	-1.59%
33 Yıllık Değişim	-30.57%
5 Yıllık Değişim	1,080.95%
Halka arzdan bu yana değişim	-55.07%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	TCE2	DE Biotechs	DE Pazar
7D	2.5%	-0.7%	-0.02%
1Y	-1.6%	-17.2%	8.2%

Getiri vs. Endüstri: TCE2 geçen yıl % -17.2 oranında getiri sağlayan German Biotechs sektörünü aştı.

Getiri vs Piyasa: TCE2 geçen yıl % 8.2 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is TCE2's price volatile compared to industry and market?
TCE2 volatility
TCE2 Average Weekly Movement	8.3%
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: TCE2 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: TCE2 'nin haftalık oynaklığı ( 8% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1983	160	Anthony Marucci	www.celldex.com

Bir biyofarmasötik şirketi olan Celldex Therapeutics, Inc. çeşitli hastalıkların tedavisi için terapötik monoklonal ve bispesifik antikorlar geliştirmektedir. İlaç adayları arasında enflamatuar, alerjik, otoimmün ve diğer yıkıcı hastalıkları olan hastaları tedavi etmek için antikor bazlı terapötikler bulunmaktadır. Şirketin klinik geliştirme programları, reseptör tirozin kinaz KIT'i bağlayan ve aktivitesini inhibe eden bir Faz II monoklonal antikor olan CDX-0159'dur.

Celldex Therapeutics, Inc. Temel Bilgiler Özeti

Celldex Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
TCE2 temel i̇stati̇sti̇kler
Piyasa değeri	€1.67b
Kazançlar(TTM)	-€147.96m
Gelir(TTM)	€9.58m

179.7x

P/S Oranı

-11.6x

F/K Oranı

TCE2 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
TCE2 gelir tablosu (TTM)
Gelir	US$9.98m
Gelir Maliyeti	US$147.04m
Brüt Kâr	-US$137.06m
Diğer Giderler	US$17.02m
Kazançlar	-US$154.08m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.32
Brüt Marj	-1,373.91%
Net Kâr Marjı	-1,544.48%
Borç/Özkaynak Oranı	0%

TCE2 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

TCE2 Stoklara Genel Bakış

Ödüller

Risk Analizi

Celldex Therapeutics, Inc. Rakipler

XTRA:BIO3

€1.4b

XTRA:FYB

€827.2m

XTRA:HPHA

€103.9m

XTRA:2INV

€63.8m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Founder recently bought €290k worth of stock

Third quarter 2024 earnings released: US$0.64 loss per share (vs US$0.81 loss in 3Q 2023)

Celldex Therapeutics, Inc. Announces Positive Results from its Phase 2 Clinical Trial of Barzolvolimab

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Recent updates

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Founder recently bought €290k worth of stock

Third quarter 2024 earnings released: US$0.64 loss per share (vs US$0.81 loss in 3Q 2023)

Celldex Therapeutics, Inc. Announces Positive Results from its Phase 2 Clinical Trial of Barzolvolimab

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.54 loss per share (vs US$0.65 loss in 2Q 2023)

Celldex Therapeutics, Inc. Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

New minor risk - Share price stability

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Senior VP & Chief Medical Officer recently sold €1.5m worth of stock

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria At Eaaci 2024

Senior VP recently sold €314k worth of stock

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

First quarter 2024 earnings released: US$0.56 loss per share (vs US$0.62 loss in 1Q 2023)

Celldex Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Celldex Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 26, 2024

Full year 2023 earnings released: US$2.92 loss per share (vs US$2.40 loss in FY 2022)

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering.

New minor risk - Shareholder dilution

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.475 million.

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering.

Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

New major risk - Share price stability

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.57 loss in 3Q 2022)

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1B Results in Prurigo Nodularis At 12Th World Congress on Itch 2023

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.65 loss per share (vs US$0.77 loss in 2Q 2022)

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis

Now 22% undervalued after recent price drop

Celldex Therapeutics, Inc. Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023

Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Study of Cdx-585 in Patients with Advanced Malignancies

Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622

First quarter 2023 earnings released: US$0.62 loss per share (vs US$0.49 loss in 1Q 2022)

Full year 2022 earnings released: US$2.40 loss per share (vs US$1.65 loss in FY 2021)

Celldex Therapeutics, Inc. Announces Appointment of Rita Jain, M.D. to Board of Directors

Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1B Study in Chronic Inducible Urticaria At Global Urticaria Forum 2022

Second quarter 2022 earnings released: US$0.77 loss per share (vs US$0.34 loss in 2Q 2021)

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex Therapeutics, Inc. Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Celldex Therapeutics, Inc. Announces Board Appointments

First quarter 2022 earnings released: US$0.49 loss per share (vs US$0.42 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis

Third quarter 2021 earnings released: US$0.45 loss per share (vs US$0.36 loss in 3Q 2020)

Celldex Therapeutics, Inc. Announces Initiation of CDX-0159 Subcutaneous Formulation Study

Second quarter 2021 earnings released: US$0.34 loss per share (vs US$0.50 loss in 2Q 2020)

Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial

Celldex Therapeutics, Inc. Announces Acceptance of Abstract for CDX-0159 Phase 1b Results in Inducible Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021